AstriVax Therapeutics
Belgium - HeverleeBiotechnology
Focus: AstriVax Therapeutics is a Belgian biotech focused on prophylactic and therapeutic vaccines for infectious diseases, operating as a public-stage company founded in 2022.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About AstriVax Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow AstriVax Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AVX70120 low dose level
Yellow FeverClinical Trials (1)
NCT06998004A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
Phase 1Help build intelligence for AstriVax Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.